N/A
Completed N=164
Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication
Source: ClinicalTrials.gov NCT02596620 ↗Enrolled (actual)
164
Serious AEs
0.0%
Results posted
Nov 2016
Primary outcomePrimary: Percentage of Participants With Successful Eradication of H. Pylori — 91.4; 81.5 percentage of eradication
Summary
Asia Pacific Consensus states that levofloxacin-based triple therapy as an alternative second-line therapy after Helicobacter pylori (H. pylori) eradication failure when bismuth salts are not available. The investigators compare the efficacies of 10-day levofloxacin-based sequential therapy and 10-day triple therapy in the treatment for patients after failure of standard triple therapy and to determine what clinical and bacterial factors influencing the efficacy of salvage regimens.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With Successful Eradication of H. Pylori |
91.4; 81.5 | — |
Eligibility Criteria
Inclusion Criteria
- Consecutive H. pylori-infected participants, at least 18 years of age, with endoscopically proven peptic ulcer diseases or gastritis who failed first-line eradication therapies with standard triple regimens (PPI twice daily, 500 mg of clarithromycin twice daily and 1 g of amoxicillin twice daily)
Exclusion Criteria
- Ingestion of antibiotics, bismuth, or proton-pump inhibitors within the prior 4 weeks
- Use of non-steroidal anti-inflammatory drugs within the prior 4 weeks
- Participants with allergic history to the medications used
- Participants with previous gastric surgery
- The coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia)
- Pregnant women.
Data sourced from ClinicalTrials.gov (NCT02596620). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.